Sangamo's High-Stakes Gamble on Gene Therapy's Future

RICHMOND, CA – March 30, 2026 – Sangamo Therapeutics finds itself at a pivotal and precarious crossroads, simultaneously advancing a potentially transformative gene therapy for Fabry disease toward regulatory approval while executing a company-wide pivot to neurology, all under the shadow of a looming financial cliff. The genomic medicine company's year-end 2025 financial report, released today, paints a stark picture of high-stakes science meeting harsh economic reality, with a cash runway that extends only into the third quarter of this year.

The company is in a race against time. On one hand, it holds promising, long-term clinical data for its Fabry disease candidate, isaralgagene civaparvovec (ST-920), and is in the midst of a rolling submission to the U.S. Food and Drug Administration (FDA). On the other, its cash and cash equivalents stood at a mere $20.9 million at the end of 2025, raising substantial doubt about its ability to continue as a going concern without securing significant new funding in the immediate future.

A Race Against Time for a Fabry Disease Breakthrough

Fabry disease is a rare genetic disorder that, left unchecked, causes progressive damage to the kidneys, heart, and nervous system. The current standard of care, enzyme replacement therapy (ERT), requires patients to endure lifelong, bi-weekly intravenous infusions. In a market valued at over $3 billion, a one-time treatment that offers a durable effect would be a paradigm shift.

Sangamo believes it has just that with ST-920. The company presented detailed data from its registrational Phase 1/2 STAAR study showing what could be a game-changer for patients. After a single administration, the gene therapy demonstrated the potential for sustained production of the missing α-Gal A enzyme. Critically, data showed a positive mean annualized eGFR slope—a measure of kidney function—at 52 weeks across all 32 dosed patients, indicating an improvement rather than the typical decline seen in the disease. This effect was observed to be durable, with stable kidney and heart function maintained for up to 4.5 years in the longest-treated patient.

Furthermore, all 18 patients who were on ERT at the start of the trial were successfully withdrawn from the burdensome infusions and have remained off them. The FDA has reiterated that this kidney function data may serve as the primary basis for approval under its Accelerated Approval pathway, a program designed to speed promising drugs for serious conditions to market. This pathway could shave years off the typical development timeline.

“Following positive topline results from our registrational STAAR study in Fabry disease, we are well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway,” said Sandy Macrae, CEO of Sangamo Therapeutics, in the company's press release.

However, this promising path is paved with uncertainty. Sangamo stated that completion of the rolling Biologics License Agreement (BLA) submission, expected as early as this summer, is contingent on its ability to secure adequate additional funding. The company is actively pursuing a commercialization partner for the Fabry program, a deal that now appears critical not only for marketing the drug but for funding its final push to the regulatory finish line.

The High Cost of Innovation

The financial pressure is immense. Sangamo reported a consolidated net loss of $122.9 million for 2025, an increase from a $97.9 million loss in 2024. While the company has raised over $130 million since the start of 2025 through various financing efforts and non-dilutive payments from partners, its operating expenses remain high as it funds late-stage manufacturing and BLA-readiness activities for the Fabry program.

The company’s financial guidance for 2026, which projects total operating expenses between $120 million and $140 million, is explicitly subject to securing more capital. This stark reality places Sangamo in a high-pressure situation where its groundbreaking science is directly tethered to its ability to convince investors or a large pharmaceutical partner to bet on its vision before the clock runs out.

Pivoting to the Brain: A Bet on Neurological Cures

Even as it pushes its lead asset forward, Sangamo is fundamentally reshaping its identity. The company has officially transitioned into a clinical-stage neurology company, a strategic pivot built upon its proprietary STAC-BBB capsid technology. This novel adeno-associated virus (AAV) capsid is engineered to efficiently cross the formidable blood-brain barrier, a holy grail for delivering therapies directly to the central nervous system.

Preclinical studies have shown the STAC-BBB capsid to be remarkably effective, demonstrating 700-fold higher transgene expression in the brain compared to the benchmark AAV9 capsid after intravenous administration. This technology underpins Sangamo’s new core pipeline, including ST-503, an epigenetic regulator for chronic neuropathic pain that has received Fast Track Designation from the FDA and is currently being evaluated in the Phase 1/2 STAND study.

This strategic shift has already attracted significant validation from major pharmaceutical players. In April 2025, Sangamo inked a licensing deal with Eli Lilly for its STAC-BBB technology, securing an $18 million upfront payment with the potential for over a billion dollars in future milestones. This followed similar deals with Roche’s Genentech and Astellas, demonstrating strong industry belief in Sangamo’s brain-targeting platform. These partnerships provide crucial non-dilutive funding that helps keep the lights on while validating the company's long-term scientific direction.

The coming months will be decisive for Sangamo Therapeutics. The company must successfully navigate a complex dual strategy: securing the necessary capital to potentially commercialize a life-changing therapy for Fabry disease while simultaneously laying the groundwork for a future centered on solving intractable neurological disorders. Success depends on convincing the market that its scientific promise is worth the considerable financial risk, a high-wire act with the fate of both patients and the company hanging in the balance.